SCALE Sleep Apnea shows liraglutide reduces apnea events

A clinical trial called SCALE Sleep Apnea found that liraglutide 3.0 mg lowered the severity of obstructive sleep apnea (OSA) more than a placebo in adults with obesity who could not or would not use a CPAP machine. Over 32 weeks, the drug cut the apnea-hypopnea index (AHI), a measure of how often breathing stops or slows during sleep, by an average of 12.2 events per hour, compared with 6.1 events per hour on placebo ^[1]. The gap between the two groups, 6.1 events per hour, was large enough to be statistically meaningful (P=0.0150) ^[1].

The study enrolled 359 adults, average age 48.5, with 71.9% male participants ^[1]. Everyone had moderate or severe OSA, meaning an average of 49.2 breathing events per hour at the start, and two-thirds had the more severe form of the condition ^[1]. Participants also had obesity, with an average body weight of 117.6 kg and a body mass index of 39.1 ^[1]. Nearly two-thirds already had prediabetes ^[1].

People taking liraglutide also lost more weight than those on placebo: 5.7% of body weight compared with 1.6% ^[1]. A follow-up analysis found that the amount of weight a person lost was statistically linked to how much their sleep apnea improved (P<0.01) ^[1]. The trial also found bigger drops in blood sugar (HbA1c) and systolic blood pressure among people on liraglutide compared with placebo (both P<0.001) ^[1]. Researchers reported that side effects at the 3.0 mg dose were similar to what has been seen at lower liraglutide doses of 1.8 mg or less ^[1].

Why it matters for patients

This trial, published in 2016 and registered as NCT01557166, showed that a GLP-1 drug could meaningfully reduce sleep apnea severity as a side effect of weight loss, not as its primary purpose ^[1]. Even so, the drug at this dose was not approved by regulators specifically to treat sleep apnea; it was studied and later marketed under the brand Saxenda mainly for weight management. That distinction matters for patients today because doctors cannot prescribe liraglutide with an FDA label that covers sleep apnea specifically, even though this data exists.

The results also show a common pattern with GLP-1 medications: the biggest health improvements, including reduced apnea events, tended to track with how much weight a person lost ^[1]. For someone with obesity and sleep apnea who is unable or unwilling to use CPAP, this study suggests weight loss achieved through a GLP-1 drug can lower AHI scores, but the reduction, roughly 6 fewer events per hour than placebo, is a partial effect, not a cure, and average AHI after treatment likely remained in a range still classified as moderate or severe for many participants, since baseline AHI averaged 49.2 events per hour ^[1].

Patients considering GLP-1 drugs for sleep apnea reasons should know this specific dose and formulation, liraglutide 3.0 mg, is not the same as the newer, higher-potency drugs now sold as Wegovy (semaglutide) or Zepbound (tirzepatide). The sources reviewed here do not address whether those newer drugs have similar or different effects on sleep apnea, so that comparison is not yet established from this study alone.

What happens next

The SCALE Sleep Apnea trial was published in 2016, and its data remain part of the evidence base for how weight-loss drugs affect sleep-related breathing problems ^[1]. The source reviewed does not indicate any subsequent regulatory filing or decision specifically adding a sleep apnea indication for liraglutide, so whether or when such an approval might occur is not known from this material.